

11/3  
AP

THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 03 2001

TECH CENTER 1600/2900

Applicant : George B. Stefano et al.

Art Unit : 1647

Serial No. : 09/530,880

Examiner : R. Landsman

Filed : September 28, 2000

Title : OPIATE, CANNABINOID, AND ESTROGEN RECEPTORS

**BOX SEQUENCE**

Commissioner for Patents

Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated July 20, 2001 (copy enclosed), applicants submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicants submit an initial Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

Applicants respectfully requests entry of the paper copy and computer readable copy of the Sequence Listing filed herewith for the instant application. Furthermore, applicants requests entry of the following amendments.

In the specification:

Insert the paper copy of the Sequence Listing filed herewith following the Oath/Declaration.

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

September 20, 2001

Date of Deposit

Jill Huso

Signature

Jill Huso

Typed or Printed Name of Person Signing Certificate

Applicant : George B. Stefano et al.  
Serial No. : 09/530,880  
Filed : September 28, 2000  
Page : 2

Attorney's Docket No. 09598-004001 / R1224-432


REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing in the specification. No new matter has been added.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: September 20, 2001

  
J. Patrick Finn III, Ph.D.  
Reg. No. 44,109

Fish & Richardson P.C., P.A.  
60 South Sixth Street  
Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Facsimile: (612) 288-9696



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 03 2001

TECH CENTER 1600/2900

Applicant : George B. Stefano et al.

Art Unit : 1647

Serial No. : 09/530,880

Examiner : R. Landsman

Filed : September 28, 2000

Title : OPIATE, CANNABINOID, AND ESTROGEN RECEPTORS

**BOX SEQUENCE**

Commissioner for Patents


Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I, Jennifer H. Payne, declare that I personally prepared the paper and the computer-readable copy of the Sequence Listing filed herewith for the above-identified application and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: September 10, 2001

  
Jennifer H. Payne


Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
(617) 542-5070 telephone  
(617) 542-8906 facsimile

20300470.doc


CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

September 20, 2001  
Date of Deposit

  
Signature

Jim Huso  
Typed or Printed Name of Person Signing Certificate



Application No.: 09/530780

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**